To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
GSK and Flagship to jointly fund up to $150 million upfront
Report highlights significant improvements in adolescent well-being in India
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Subscribe To Our Newsletter & Stay Updated
